P014 Interim analysis of ELEANOR (n = 200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+ and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

oleh: R. Bartsch, N. Harbeck, D. Wrobel, M. Zaiss, J. Terhaag, D. Guth, A. Distelrath, R. Wuerstlein, M.-O. Zahn, D. Lüftner, M. Schwitter, M. Balic, C. Jackisch, V. Müller, G. Rinnerthaler, M. Schmidt, K. Zaman, T. Schinköthe, M. Gorray, U. Breitenstein